UCB, a global biopharmaceutical company, has announced its intention to acquire Zymvol Biomarker Research, a company specializing in the development of antibody treatments for autoimmune diseases. The acquisition is expected to enhance UCB’s existing portfolio in this therapeutic area.
The deal comes at a time when the U.S. biotech sector is grappling with the consequences of stricter immigration policies. Visa delays and growing uncertainty are increasingly deterring international scientists from pursuing opportunities in the country, potentially impacting innovation and research output.
Zymvol Biomarker Research, based in the United Kingdom, is recognized for its expertise in antibody-based therapies, particularly in addressing conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. The company’s pipeline includes several promising candidates that align with UCB’s strategic focus on immunology and inflammation.
Financial terms of the acquisition have not been disclosed. However, UCB has confirmed that the deal is expected to close in the second half of 2024, subject to regulatory approvals and customary closing conditions.
In a statement, Jean-Christophe Tellier, CEO of UCB, emphasized the significance of the acquisition:
“This acquisition underscores our commitment to advancing innovative treatments for patients with autoimmune diseases. Zymvol’s expertise in antibody development complements our existing capabilities and strengthens our ability to deliver transformative therapies.”
The announcement follows a series of strategic moves by UCB to bolster its position in the immunology market. Earlier this year, the company received FDA approval for Bimzelx (bimekizumab-bkzx), a treatment for moderate to severe plaque psoriasis, further solidifying its leadership in the field.
Meanwhile, the biotech industry continues to navigate challenges, including regulatory hurdles, supply chain disruptions, and the evolving landscape of global talent acquisition. The acquisition of Zymvol Biomarker Research reflects UCB’s proactive approach to addressing these challenges while advancing its mission to improve the lives of patients worldwide.
Related articles
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...